WLG
VRTX icon

Williamson Legacy Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Williamson Legacy Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,576
Closed -$1.08M – 115
2024
Q1 		$1.08M Sell
2,576
-8
-0.3% -$3.38K 0.83% 36
2023
Q4 		$1.05M Buy
+2,584
New +$955K 0.97% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Williamson Legacy Group's VRTX Position: Q2 2024 in Review

Williamson Legacy Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 2,576 shares — an estimated $1.08M sold.

Williamson Legacy Group first reported a position in VRTX in Q4 2023 and held it in 2 quarters. The position peaked at $1.08M in Q1 2024. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Williamson Legacy Group reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Williamson Legacy Group sold 2,576 Vertex Pharmaceuticals shares in Q2 2024, an estimated $1.08M.
  • Williamson Legacy Group first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Williamson Legacy Group's Vertex Pharmaceuticals position peaked at $1.08M in Q1 2024.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Williamson Legacy Group's 13F filing for Q2 2024, filed 14 Aug 2024.